Accession Number:

ADA416167

Title:

Use of Erb-2 Mimotopes for Breast Cancer Immunotherapy

Descriptive Note:

Annual rept. 15 Jun 2001-14 Jun 2002

Corporate Author:

WAYNE STATE UNIV DETROIT MI DEPT OF BIOLOGICAL SCIENCES

Personal Author(s):

Report Date:

2002-07-01

Pagination or Media Count:

7.0

Abstract:

Recently a new drug Herceptin has been shown to be effective in the treatment of malignant breast cancer and has been approved for use. Herceptin is essentially a humanized mouse monoclonal antibody that binds to ErbB-2, a membrane growth factor receptor, tyrosine kinase, that is overexpressed in 25-30 of patients with malignant breast cancer. Herceptin prevents targeted cells from proliferating. The authors goal is to induce the body to produce its own antibodies to ErbB-2, which, like Herceptin, will target breast cancer cells and prevent them from growing. The specific purpose of this proposal is to test the use of phage particle mimotopes of ErbB-2 to make a vaccine, which when injected into mice, will induce the animals to make antibodies against ErbB-2. Progress so far has included the development of a phage selection protocol, and the subsequent collection of M13 phage clones that have high affinity for binding to Herceptin, and thus likely will constitute effective mimotopes to ErbB-2. 2 figures, 3 refs.

Subject Categories:

  • Anatomy and Physiology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE